about
Adoptive immunotherapy against ovarian cancerIL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.Evaluation of MHC class I peptide binding prediction servers: applications for vaccine researchRegulation of cancer germline antigen gene expression: implications for cancer immunotherapy.In-vitro activation of cytotoxic T lymphocytes by fusion of mouse hepatocellular carcinoma cells and lymphotactin gene-modified dendritic cells.Immunotherapy for ovarian cancer: what's next?Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.Immunotherapy of cancer in 2012.Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer.The impact of T-cell immunity on ovarian cancer outcomes.Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicineDevelopmentally restricted differentiation antigens are targets for immunotherapy in epithelial ovarian carcinoma.Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer.Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes.Vaccine-based clinical trials in ovarian cancer.Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.
P2860
Q26748905-1ED6FDAB-AA22-4DDB-A7AA-A610550EB1D4Q30355682-E5597B32-10E1-425E-BEA0-128D3DF90AF8Q33325636-26864152-2F45-4A20-A338-593C1026AB8DQ33957165-E2504B99-9EC8-4CCF-914F-11D4EBCB7380Q34382848-D517BCF3-95A0-4170-B644-D2531B9D8F77Q34743514-EC1228F2-12E1-4A54-86E9-3066973DD8F6Q35793791-DB0C0342-361E-48AD-A0E0-C4F2D6FECA29Q36243536-C4E40C13-9082-486C-9B8C-DACAABA8B57EQ36977523-0005A409-877A-4E53-8820-447DE2AD0692Q37118142-FE341676-1080-4739-BE1E-A855938ECB56Q37224420-4F256448-2113-42C7-9BB0-6E3D7E9F7EA1Q37305459-4FE8DDAE-85C5-44CC-9B3C-11AA222101BDQ37326840-4E1E0374-1998-4853-B2BE-6A6D38370F28Q37332250-02F15D8A-1032-4AF2-9979-74BA248DCC0FQ37369523-4016B8AF-B17B-4380-A6A0-1537CE305540Q37424014-336E4890-7103-4F54-99D8-AF74CA4F03AFQ37892583-C4DAF915-5697-4126-9D1C-2A3D4988F495Q47993135-B309CADF-6F69-4C27-8BD0-D8750A8607CD
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Immunologic approaches to ovarian cancer treatment.
@en
type
label
Immunologic approaches to ovarian cancer treatment.
@en
prefLabel
Immunologic approaches to ovarian cancer treatment.
@en
P356
P1476
Immunologic approaches to ovarian cancer treatment.
@en
P2093
Paul Sabbatini
P304
P356
10.1200/JCO.2007.11.0775
P407
P50
P577
2007-07-01T00:00:00Z